Lessons learned from successful human vaccines: Delineating key epitopes by dissecting the capsid proteins

References

• Grgacic EV, Anderson DA. Virus-like particles: passport to immune recognition. Methods 2006; 40:60-5; PMID:16997714; http://dx.doi.org/10.1016/j.ymeth.2006.07.018
   PubMed Web of Science ®Google Scholar
• Chuan YP, Rivera-Hernandez T, Wibowo N, Connors NK, Wu Y, Hughes FK, Lua LH, Middelberg AP. Effects of pre-existing anti-carrier immunity and antigenic element multiplicity on efficacy of a modular virus-like particle vaccine. Biotechnol Bioeng 2013; 110:2343-51; PMID:23532896; http://dx.doi.org/10.1002/bit.24907
   PubMed Web of Science ®Google Scholar
• Steinmetz NF. Viral nanoparticles as platforms for next-generation therapeutics and imaging devices. Nanomedicine 2010; 6:634-41; PMID:20433947; http://dx.doi.org/10.1016/j.nano.2010.04.005
   PubMed Web of Science ®Google Scholar
• Zhao Q, Li S, Yu H, Xia N, Modis Y. Virus-like particle-based human vaccines: quality assessment based on structural and functional properties. Trend Biotechnol 2013; 31:654-63; PMID:24125746; http://dx.doi.org/10.1016/j.tibtech.2013.09.002
   PubMed Web of Science ®Google Scholar
• Ma Y, Nolte RJ, Cornelissen JJ. Virus-based nanocarriers for drug delivery. Adv Drug Deliv Rev 2012; 64:811-25; PMID:22285585; http://dx.doi.org/10.1016/j.addr.2012.01.005
   PubMed Web of Science ®Google Scholar
• Tan M, Jiang X. Subviral particle as vaccine and vaccine platform. Curr Opin Virol 2014; 6C:24-33; PMID:24662314; http://dx.doi.org/10.1016/j.coviro.2014.02.009
   PubMedGoogle Scholar
• Zeltins A. Construction and characterization of virus-like particles: a review. Mol Biotechnol 2013; 53:92-107; PMID:23001867; http://dx.doi.org/10.1007/s12033-012-9598-4
   PubMed Web of Science ®Google Scholar
• Li SW, Zhang J, Li YM, Ou SH, Huang GY, He ZQ, Ge SX, Xian YL, Pang SQ, Ng MH, et al. A bacterially expressed particulate hepatitis E vaccine: antigenicity, immunogenicity and protectivity on primates. Vaccine 2005; 23:2893-901; PMID:15780738; http://dx.doi.org/10.1016/j.vaccine.2004.11.064
   PubMed Web of Science ®Google Scholar
• Zhu FC, Zhang J, Zhang XF, Zhou C, Wang ZZ, Huang SJ, Wang H, Yang CL, Jiang HM, Cai JP, et al. Efficacy and safety of a recombinant hepatitis E vaccine in healthy adults: a large-scale, randomised, double-blind placebo-controlled, phase 3 trial. Lancet 2010; 376:895-902; PMID:20728932; http://dx.doi.org/10.1016/S0140-6736(10)61030-6
   PubMed Web of Science ®Google Scholar
• Zhang J, Liu CB, Li RC, Li YM, Zheng YJ, Li YP, Luo D, Pan BB, Nong Y, Ge SX, et al. Randomized-controlled phase II clinical trial of a bacterially expressed recombinant hepatitis E vaccine. Vaccine 2009; 27:1869-74; PMID:19168109; http://dx.doi.org/10.1016/j.vaccine.2008.12.061
   PubMed Web of Science ®Google Scholar
• Shrestha MP, Scott RM, Joshi DM, Mammen MP, Jr., Thapa GB, Thapa N, Myint KS, Fourneau M, Kuschner RA, Shrestha SK, et al. Safety and efficacy of a recombinant hepatitis E vaccine. N Engl J Med 2007; 356:895-903; PMID:17329696; http://dx.doi.org/10.1056/NEJMoa061847
   PubMed Web of Science ®Google Scholar
• Joura EA, Leodolter S, Hernandez-Avila M, Wheeler CM, Perez G, Koutsky LA, Garland SM, Harper DM, Tang GW, Ferris DG, et al. Efficacy of a quadrivalent prophylactic human papillomavirus (types 6, 11, 16, and 18) L1 virus-like-particle vaccine against high-grade vulval and vaginal lesions: a combined analysis of three randomised clinical trials. Lancet 2007; 369:1693-702; PMID:17512854; http://dx.doi.org/10.1016/S0140-6736(07)60777-6
   PubMed Web of Science ®Google Scholar
• Paavonen J, Naud P, Salmeron J, Wheeler CM, Chow SN, Apter D, Kitchener H, Castellsague X, Teixeira JC, Skinner SR, et al. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet 2009; 374:301-14; PMID:19586656; http://dx.doi.org/10.1016/S0140-6736(09)61248-4
   PubMed Web of Science ®Google Scholar
• Li S, Tang X, Seetharaman J, Yang C, Gu Y, Zhang J, Du H, Shih JW, Hew CL, Sivaraman J, et al. Dimerization of hepatitis E virus capsid protein E2s domain is essential for virus-host interaction. PLoS Pathog 2009; 5:e1000537; PMID:19662165; http://dx.doi.org/10.1371/journal.ppat.1000537
   PubMed Web of Science ®Google Scholar
• Yamashita T, Mori Y, Miyazaki N, Cheng RH, Yoshimura M, Unno H, Shima R, Moriishi K, Tsukihara T, Li TC, et al. Biological and immunological characteristics of hepatitis E virus-like particles based on the crystal structure. Proc Natl Acad Sci U S A 2009; 106:12986-91; PMID:19620712; http://dx.doi.org/10.1073/pnas.0903699106
   PubMed Web of Science ®Google Scholar
• Tang X, Yang C, Gu Y, Song C, Zhang X, Wang Y, Zhang J, Hew CL, Li S, Xia N, et al. Structural basis for the neutralization and genotype specificity of hepatitis E virus. Proc Natl Acad Sci U S A 2011; 108:10266-71; PMID:21642534; http://dx.doi.org/10.1073/pnas.1101309108
   PubMed Web of Science ®Google Scholar
• Xing L, Wang JC, Li TC, Yasutomi Y, Lara J, Khudyakov Y, Schofield D, Emerson SU, Purcell RH, Takeda N, et al. Spatial configuration of hepatitis E virus antigenic domain. J Virol 2011; 85:1117-24; PMID:21068233; http://dx.doi.org/10.1128/JVI.00657-10
   PubMed Web of Science ®Google Scholar
• Gu Y, Tang X, Zhang X, Li S, Xia N. Structural Basis for the Neutralization of Hepatitis E Virus by a Cross-genotype Antibody. Cell Research 2015; 34:xxx-xxx. doi:10.1038/cr.2015.34.
   Web of Science ®Google Scholar
• Zhao Q, Potter CS, Carragher B, Lander G, Sworen J, Towne V, Abraham D, Duncan P, Washabaugh MW, Sitrin RD. Characterization of virus-like particles in GARDASIL(R) by cryo transmission electron microscopy. Hum Vaccin Immunother 2013; 10:734-9; PMID:24299977; http://dx.doi.org/10.4161/hv.27316
   PubMedGoogle Scholar
• Christensen ND, Dillner J, Eklund C, Carter JJ, Wipf GC, Reed CA, Cladel NM, Galloway DA. Surface conformational and linear epitopes on HPV-16 and HPV-18 L1 virus-like particles as defined by monoclonal antibodies. Virology 1996; 223:174-84; PMID:8806551; http://dx.doi.org/10.1006/viro.1996.0466
   PubMed Web of Science ®Google Scholar
• Wei M, Zhang X, Yu H, Tang ZM, Wang K, Li Z, Zheng Z, Li S, Zhang J, Xia N, et al. Bacteria expressed hepatitis E virus capsid proteins maintain virion-like epitopes. Vaccine 2014; 32:2859-65; PMID:24662711; http://dx.doi.org/10.1016/j.vaccine.2014.02.025
   PubMed Web of Science ®Google Scholar
• Pastrana DV, Buck CB, Pang YY, Thompson CD, Castle PE, FitzGerald PC, Kruger Kjaer S, Lowy DR, Schiller JT. Reactivity of human sera in a sensitive, high-throughput pseudovirus-based papillomavirus neutralization assay for HPV16 and HPV18. Virology 2004; 321:205-16; PMID:15051381; http://dx.doi.org/10.1016/j.virol.2003.12.027
   PubMed Web of Science ®Google Scholar
• Zhang J, Li SW, Wu T, Zhao Q, Ng MH, Xia NS. Hepatitis E virus: neutralizing sites, diagnosis, and protective immunity. Rev Med Virol 2012; 22:339-49; PMID:22645002; http://dx.doi.org/10.1002/rmv.1719
   PubMed Web of Science ®Google Scholar
• Robinson RA, Burgess WH, Emerson SU, Leibowitz RS, Sosnovtseva SA, Tsarev S, Purcell RH. Structural characterization of recombinant hepatitis E virus ORF2 proteins in baculovirus-infected insect cells. Protein Expr Purif 1998; 12:75-84; PMID:9473460; http://dx.doi.org/10.1006/prep.1997.0817
   PubMed Web of Science ®Google Scholar
• Zhang M, Emerson SU, Nguyen H, Engle RE, Govindarajan S, Gerin JL, Purcell RH. Immunogenicity and protective efficacy of a vaccine prepared from 53 kDa truncated hepatitis E virus capsid protein expressed in insect cells. Vaccine 2001; 20:853-7; PMID:11738749; http://dx.doi.org/10.1016/S0264-410X(01)00399-1
   PubMed Web of Science ®Google Scholar
• Wu T, Li SW, Zhang J, Ng MH, Xia NS, Zhao Q. Hepatitis E vaccine development: a 14 year odyssey. Hum Vacci Immunother 2012; 8:823-7; PMID:22699438; http://dx.doi.org/10.4161/hv.20042
   PubMed Web of Science ®Google Scholar
• Wu T, Zhu FC, Huang SJ, Zhang XF, Wang ZZ, Zhang J, Xia NS. Safety of the hepatitis E vaccine for pregnant women: a preliminary analysis. Hepatology 2012; 55:2038; PMID:22161542; http://dx.doi.org/10.1002/hep.25522
   PubMed Web of Science ®Google Scholar
• Wu T, Huang SJ, Zhu FC, Zhang XF, Ai X, Yan Q, Wang ZZ, Yang CL, Jiang HM, Liu XH, et al. Immunogenicity and safety of hepatitis E vaccine in healthy hepatitis B surface antigen positive adults. Hum Vacci Immunother 2013; 9:2474-9; PMID:23887167; http://dx.doi.org/10.4161/hv.25814
   PubMed Web of Science ®Google Scholar
• Krain LJ, Nelson KE, Labrique AB. Host immune status and response to hepatitis E virus infection. Clin Microbiol Rre 2014; 27:139-65; PMID:24396140; http://dx.doi.org/10.1128/CMR.00062-13
   PubMed Web of Science ®Google Scholar
• Zhou YH, Purcell RH, Emerson SU. A truncated ORF2 protein contains the most immunogenic site on ORF2: antibody responses to non-vaccine sequences following challenge of vaccinated and non-vaccinated macaques with hepatitis E virus. Vaccine 2005; 23:3157-65; PMID:15837215; http://dx.doi.org/10.1016/j.vaccine.2004.12.020
   PubMed Web of Science ®Google Scholar
• Zhang X, Wei M, Pan H, Lin Z, Wang K, Weng Z, Zhu Y, Xin L, Zhang J, Li S, et al. Robust manufacturing and comprehensive characterization of recombinant hepatitis E virus-like particles in Hecolin((R)). Vaccine 2014; 32:4039-50; PMID:24892250; http://dx.doi.org/10.1016/j.vaccine.2014.05.064
   PubMed Web of Science ®Google Scholar
• Khudyakov YE, Lopareva EN, Jue DL, Crews TK, Thyagarajan SP, Fields HA. Antigenic domains of the open reading frame 2-encoded protein of hepatitis E virus. J Clin Microbiol 1999; 37:2863-71; PMID:10449466
   PubMed Web of Science ®Google Scholar
• Zhang H, Dai X, Shan X, Meng J. Characterization of antigenic epitopes of the ORF2 protein from hepatitis E virus genotype 4. Virus Res 2009; 142:140-3; PMID:19428747; http://dx.doi.org/10.1016/j.virusres.2009.02.002
   PubMedGoogle Scholar
• Khudyakov Yu E, Favorov MO, Jue DL, Hine TK, Fields HA. Immunodominant antigenic regions in a structural protein of the hepatitis E virus. Virology 1994; 198:390-3; PMID:8259678; http://dx.doi.org/10.1006/viro.1994.1048
   PubMed Web of Science ®Google Scholar
• Li F, Torresi J, Locarnini SA, Zhuang H, Zhu W, Guo X, Anderson DA. Amino-terminal epitopes are exposed when full-length open reading frame 2 of hepatitis E virus is expressed in Escherichia coli, but carboxy-terminal epitopes are masked. J Med Virol 1997; 52:289-300; PMID:9210039; http://dx.doi.org/10.1002/(SICI)1096-9071(199707)52:3%3c289::AID-JMV10%3e3.0.CO;2-E
   PubMed Web of Science ®Google Scholar
• Riddell MA, Li F, Anderson DA. Identification of immunodominant and conformational epitopes in the capsid protein of hepatitis E virus by using monoclonal antibodies. J Virol 2000; 74:8011-7; PMID:10933710; http://dx.doi.org/10.1128/JVI.74.17.8011-8017.2000
   PubMedGoogle Scholar
• Meng J, Dai X, Chang JC, Lopareva E, Pillot J, Fields HA, Khudyakov YE. Identification and characterization of the neutralization epitope(s) of the hepatitis E virus. Virology 2001; 288:203-11; PMID:11601892; http://dx.doi.org/10.1006/viro.2001.1093
   PubMed Web of Science ®Google Scholar
• Zhang JZ, Ng MH, Xia NS, Lau SH, Che XY, Chau TN, Lai ST, Im SW. Conformational antigenic determinants generated by interactions between a bacterially expressed recombinant peptide of the hepatitis E virus structural protein. J Med Virol 2001; 64:125-32; PMID:11360244; http://dx.doi.org/10.1002/jmv.1027
   PubMed Web of Science ®Google Scholar
• Emerson SU, Clemente-Casares P, Moiduddin N, Arankalle VA, Torian U, Purcell RH. Putative neutralization epitopes and broad cross-genotype neutralization of Hepatitis E virus confirmed by a quantitative cell-culture assay. J Gen Virol 2006; 87:697-704; PMID:16476993; http://dx.doi.org/10.1099/vir.0.81545-0
   PubMed Web of Science ®Google Scholar
• Zhang H, Dai X, Shan X, Meng J. The Leu477 and Leu613 of ORF2-encoded protein are critical in forming neutralization antigenic epitope of hepatitis E virus genotype 4. Cell Mol Immunol 2008; 5:447-56; PMID:19118511; http://dx.doi.org/10.1038/cmi.2008.56
   PubMed Web of Science ®Google Scholar
• Rose RC, Reichman RC, Bonnez W. Human papillomavirus (HPV) type 11 recombinant virus-like particles induce the formation of neutralizing antibodies and detect HPV-specific antibodies in human sera. J Gen Virol 1994; 75 ( Pt 8):2075-9; PMID:8046412; http://dx.doi.org/10.1099/0022-1317-75-8-2075
   PubMedGoogle Scholar
• Thones N, Herreiner A, Schadlich L, Piuko K, Muller M. A direct comparison of human papillomavirus type 16 L1 particles reveals a lower immunogenicity of capsomeres than viruslike particles with respect to the induced antibody response. J Virol 2008; 82:5472-85; PMID:18385253; http://dx.doi.org/10.1128/JVI.02482-07
   PubMed Web of Science ®Google Scholar
• Koutsky LA, Ault KA, Wheeler CM, Brown DR, Barr E, Alvarez FB, Chiacchierini LM, Jansen KU, Proof of Principle Study I. A controlled trial of a human papillomavirus type 16 vaccine. N Engl J Med 2002; 347:1645-51; PMID:12444178; http://dx.doi.org/10.1056/NEJMoa020586
   PubMed Web of Science ®Google Scholar
• Harro CD, Pang YY, Roden RB, Hildesheim A, Wang Z, Reynolds MJ, Mast TC, Robinson R, Murphy BR, Karron RA, et al. Safety and immunogenicity trial in adult volunteers of a human papillomavirus 16 L1 virus-like particle vaccine. J Natl Cancer Inst 2001; 93:284-92; PMID:11181775; http://dx.doi.org/10.1093/jnci/93.4.284
   PubMed Web of Science ®Google Scholar
• Villa LL, Costa RL, Petta CA, Andrade RP, Paavonen J, Iversen OE, Olsson SE, Hoye J, Steinwall M, Riis-Johannessen G, et al. High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up. Br J Cancer 2006; 95:1459-66; PMID:17117182; http://dx.doi.org/10.1038/sj.bjc.6603469
   PubMed Web of Science ®Google Scholar
• Safaeian M, Porras C, Pan Y, Kreimer A, Schiller JT, Gonzalez P, Lowy DR, Wacholder S, Schiffman M, Rodriguez AC, et al. Durable antibody responses following one dose of the bivalent human papillomavirus L1 virus-like particle vaccine in the Costa Rica Vaccine Trial. Cancer Prevent Res 2013; 6:1242-50; PMID:24189371; http://dx.doi.org/10.1158/1940-6207.CAPR-13-0203
   PubMed Web of Science ®Google Scholar
• Perez G, Lazcano-Ponce E, Hernandez-Avila M, Garcia PJ, Munoz N, Villa LL, Bryan J, Taddeo FJ, Lu S, Esser MT, et al. Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) L1 virus-like-particle vaccine in Latin American women. Int J Cancer 2008; 122:1311-8; PMID:18000825; http://dx.doi.org/10.1002/ijc.23260
   PubMed Web of Science ®Google Scholar
• Harper DM, Franco EL, Wheeler CM, Moscicki AB, Romanowski B, Roteli-Martins CM, Jenkins D, Schuind A, Costa Clemens SA, Dubin G, et al. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet 2006; 367:1247-55; PMID:16631880; http://dx.doi.org/10.1016/S0140-6736(06)68439-0
   PubMed Web of Science ®Google Scholar
• Munoz N, Manalastas R, Jr., Pitisuttithum P, Tresukosol D, Monsonego J, Ault K, Clavel C, Luna J, Myers E, Hood S, et al. Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine in women aged 24-45 years: a randomised, double-blind trial. Lancet 2009; 373:1949-57; PMID:19493565; http://dx.doi.org/10.1016/S0140-6736(09)60691-7
   PubMed Web of Science ®Google Scholar
• Paavonen J, Jenkins D, Bosch FX, Naud P, Salmeron J, Wheeler CM, Chow SN, Apter DL, Kitchener HC, Castellsague X, et al. Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial. Lancet 2007; 369:2161-70; PMID:17602732; http://dx.doi.org/10.1016/S0140-6736(07)60946-5
   PubMed Web of Science ®Google Scholar
• Villa LL, Costa RL, Petta CA, Andrade RP, Ault KA, Giuliano AR, Wheeler CM, Koutsky LA, Malm C, Lehtinen M, et al. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol 2005; 6:271-8; PMID:15863374; http://dx.doi.org/10.1016/S1470-2045(05)70101-7
   PubMed Web of Science ®Google Scholar
• Markowitz LE, Hariri S, Lin C, Dunne EF, Steinau M, McQuillan G, Unger ER. Reduction in human papillomavirus (HPV) prevalence among young women following HPV vaccine introduction in the United States, National Health and Nutrition Examination Surveys, 2003-2010. J Infect Dis 2013; 208:385-93; PMID:23785124; http://dx.doi.org/10.1093/infdis/jit192
   PubMed Web of Science ®Google Scholar
• Robbins HA, Kemp TJ, Porras C, Rodriguez AC, Schiffman M, Wacholder S, Gonzalez P, Schiller J, Lowy D, Poncelet S, et al. Comparison of antibody responses to human papillomavirus vaccination as measured by three assays. Front Oncol 2014; 3:328; PMID:24455487; http://dx.doi.org/10.3389/fonc.2013.00328
   PubMedGoogle Scholar
• Bryan JT, Jansen KU, Lowe RS, Fife KH, McClowry T, Glass D, Brown DR. Human papillomavirus type 11 neutralization in the athymic mouse xenograft system: correlation with virus-like particle IgG concentration. J Med Virol 1997; 53:185-8; PMID:9365880; http://dx.doi.org/10.1002/(SICI)1096-9071(199711)53:3%3c185::AID-JMV1%3e3.0.CO;2-4
   PubMed Web of Science ®Google Scholar
• Christensen ND, Kreider JW, Cladel NM, Patrick SD, Welsh PA. Monoclonal antibody-mediated neutralization of infectious human papillomavirus type 11. J Virol 1990; 64:5678-81; PMID:2170694
   PubMed Web of Science ®Google Scholar
• Kreider JW, Howett MK, Wolfe SA, Bartlett GL, Zaino RJ, Sedlacek T, Mortel R. Morphological transformation in vivo of human uterine cervix with papillomavirus from condylomata acuminata. Nature 1985; 317:639-41; PMID:2997616; http://dx.doi.org/10.1038/317639a0
   PubMed Web of Science ®Google Scholar
• Olcese VA, Chen Y, Schlegel R, Yuan H. Characterization of HPV16 L1 loop domains in the formation of a type-specific, conformational epitope. BMC Microbiol 2004; 4:29; PMID:15260888; http://dx.doi.org/10.1186/1471-2180-4-29
   PubMedGoogle Scholar
• Slupetzky K, Shafti-Keramat S, Lenz P, Brandt S, Grassauer A, Sara M, Kirnbauer R. Chimeric papillomavirus-like particles expressing a foreign epitope on capsid surface loops. J Gen Virol 2001; 82:2799-804; PMID:11602792
   PubMed Web of Science ®Google Scholar
• Chen HS, Bromberg-White J, Conway MJ, Alam S, Meyers C. Study of infectious virus production from HPV18/16 capsid chimeras. Virology 2010; 405:289-99; PMID:20598725; http://dx.doi.org/10.1016/j.virol.2010.05.019
   PubMedGoogle Scholar
• Sadeyen JR, Tourne S, Shkreli M, Sizaret PY, Coursaget P. Insertion of a foreign sequence on capsid surface loops of human papillomavirus type 16 virus-like particles reduces their capacity to induce neutralizing antibodies and delineates a conformational neutralizing epitope. Virology 2003; 309:32-40; PMID:12726724; http://dx.doi.org/10.1016/S0042-6822(02)00134-4
   PubMed Web of Science ®Google Scholar
• Christensen ND, Cladel NM, Reed CA, Budgeon LR, Embers ME, Skulsky DM, McClements WL, Ludmerer SW, Jansen KU. Hybrid papillomavirus L1 molecules assemble into virus-like particles that reconstitute conformational epitopes and induce neutralizing antibodies to distinct HPV types. Virology 2001; 291:324-34; PMID:11878901; http://dx.doi.org/10.1006/viro.2001.1220
   PubMed Web of Science ®Google Scholar
• Roden RB, Armstrong A, Haderer P, Christensen ND, Hubbert NL, Lowy DR, Schiller JT, Kirnbauer R. Characterization of a human papillomavirus type 16 variant-dependent neutralizing epitope. J Virol 1997; 71:6247-52; PMID:9223527
   PubMed Web of Science ®Google Scholar
• White WI, Wilson SD, Palmer-Hill FJ, Woods RM, Ghim SJ, Hewitt LA, Goldman DM, Burke SJ, Jenson AB, Koenig S, et al. Characterization of a major neutralizing epitope on human papillomavirus type 16 L1. J Virol 1999; 73:4882-9; PMID:10233949
   PubMed Web of Science ®Google Scholar
• Carpentier GS, Fleury MJ, Touze A, Sadeyen JR, Tourne S, Sizaret PY, Coursaget P. Mutations on the FG surface loop of human papillomavirus type 16 major capsid protein affect recognition by both type-specific neutralizing antibodies and cross-reactive antibodies. J Med Virol 2005; 77:558-65; PMID:16254978; http://dx.doi.org/10.1002/jmv.20492
   PubMedGoogle Scholar
• Carter JJ, Wipf GC, Benki SF, Christensen ND, Galloway DA. Identification of a human papillomavirus type 16-specific epitope on the C-terminal arm of the major capsid protein L1. J Virol 2003; 77:11625-32; PMID:14557648; http://dx.doi.org/10.1128/JVI.77.21.11625-11632.2003
   PubMedGoogle Scholar
• Carter JJ, Wipf GC, Madeleine MM, Schwartz SM, Koutsky LA, Galloway DA. Identification of human papillomavirus type 16 L1 surface loops required for neutralization by human sera. J Virol 2006; 80:4664-72; PMID:16641259; http://dx.doi.org/10.1128/JVI.80.10.4664-4672.2006
   PubMed Web of Science ®Google Scholar
• Cardone G, Moyer AL, Cheng N, Thompson CD, Dvoretzky I, Lowy DR, Schiller JT, Steven AC, Buck CB, Trus BL. Maturation of the human papillomavirus 16 capsid. mBio 2014; 5:e01104-14; PMID:25096873
   PubMed Web of Science ®Google Scholar
• Marais DJ, Sampson C, Jeftha A, Dhaya D, Passmore JA, Denny L, Rybicki EP, Van Der Walt E, Stephen LX, Williamson AL. More men than women make mucosal IgA antibodies to Human papillomavirus type 16 (HPV-16) and HPV-18: a study of oral HPV and oral HPV antibodies in a normal healthy population. BMC Infect Dis 2006; 6:95; PMID:16762074; http://dx.doi.org/10.1186/1471-2334-6-95
   PubMedGoogle Scholar
• Group FIIS, Dillner J, Kjaer SK, Wheeler CM, Sigurdsson K, Iversen OE, Hernandez-Avila M, Perez G, Brown DR, Koutsky LA, et al. Four year efficacy of prophylactic human papillomavirus quadrivalent vaccine against low grade cervical, vulvar, and vaginal intraepithelial neoplasia and anogenital warts: randomised controlled trial. BMJ 2010; 341:c3493; PMID:20647284; http://dx.doi.org/10.1136/bmj.c3493
   PubMedGoogle Scholar
• Ali H, Donovan B, Wand H, Read TR, Regan DG, Grulich AE, Fairley CK, Guy RJ. Genital warts in young Australians five years into national human papillomavirus vaccination programme: national surveillance data. Bmj 2013; 346:f2032; PMID:23599298; http://dx.doi.org/10.1136/bmj.f2032
   PubMed Web of Science ®Google Scholar
• Munoz N, Kjaer SK, Sigurdsson K, Iversen OE, Hernandez-Avila M, Wheeler CM, Perez G, Brown DR, Koutsky LA, Tay EH, et al. Impact of human papillomavirus (HPV)-6/11/16/18 vaccine on all HPV-associated genital diseases in young women. J Natl Cancer Inst 2010; 102:325-39; PMID:20139221; http://dx.doi.org/10.1093/jnci/djp534
   PubMed Web of Science ®Google Scholar
• Garland SM, Hernandez-Avila M, Wheeler CM, Perez G, Harper DM, Leodolter S, Tang GW, Ferris DG, Steben M, Bryan J, et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med 2007; 356:1928-43; PMID:17494926; http://dx.doi.org/10.1056/NEJMoa061760
   PubMed Web of Science ®Google Scholar
• Christensen ND, Reed CA, Cladel NM, Hall K, Leiserowitz GS. Monoclonal antibodies to HPV-6 L1 virus-like particles identify conformational and linear neutralizing epitopes on HPV-11 in addition to type-specific epitopes on HPV-6. Virology 1996; 224:477-86; PMID:8874508; http://dx.doi.org/10.1006/viro.1996.0554
   PubMed Web of Science ®Google Scholar
• McClements WL, Wang XM, Ling JC, Skulsky DM, Christensen ND, Jansen KU, Ludmerer SW. A novel human papillomavirus type 6 neutralizing domain comprising two discrete regions of the major capsid protein L1. Virology 2001; 289:262-8; PMID:11689049; http://dx.doi.org/10.1006/viro.2001.1146
   PubMedGoogle Scholar
• Christensen ND, Hopfl R, DiAngelo SL, Cladel NM, Patrick SD, Welsh PA, Budgeon LR, Reed CA, Kreider JW. Assembled baculovirus-expressed human papillomavirus type 11 L1 capsid protein virus-like particles are recognized by neutralizing monoclonal antibodies and induce high titres of neutralizing antibodies. J Gen Virol 1994; 75 ( Pt 9):2271-6; PMID:7521393; http://dx.doi.org/10.1099/0022-1317-75-9-2271
   PubMed Web of Science ®Google Scholar
• Ludmerer SW, Benincasa D, Mark GE, 3rd. Two amino acid residues confer type specificity to a neutralizing, conformationally dependent epitope on human papillomavirus type 11. J Virol 1996; 70:4791-4; PMID:8676509
   PubMed Web of Science ®Google Scholar
• Ludmerer SW, Benincasa D, Mark GE,3rd, Christensen ND. A neutralizing epitope of human papillomavirus type 11 is principally described by a continuous set of residues which overlap a distinct linear, surface-exposed epitope. J Virol 1997; 71:3834-9; PMID:9094659
   PubMed Web of Science ®Google Scholar
• Ludmerer SW, McClements WL, Wang XM, Ling JC, Jansen KU, Christensen ND. HPV11 mutant virus-like particles elicit immune responses that neutralize virus and delineate a novel neutralizing domain. Virology 2000; 266:237-45; PMID:10639310; http://dx.doi.org/10.1006/viro.1999.0083
   PubMedGoogle Scholar
• Serrano B, Alemany L, Tous S, Bruni L, Clifford GM, Weiss T, Bosch FX, de Sanjose S. Potential impact of a nine-valent vaccine in human papillomavirus related cervical disease. Infect Agent Cancer 2012; 7:38; PMID:23273245; http://dx.doi.org/10.1186/1750-9378-7-38
   PubMed Web of Science ®Google Scholar
• Fleury MJ, Touze A, Maurel MC, Moreau T, Coursaget P. Identification of neutralizing conformational epitopes on the human papillomavirus type 31 major capsid protein and functional implications. Protein Sci 2009; 18:1425-38; PMID:19533761; http://dx.doi.org/10.1002/pro.156
   PubMedGoogle Scholar
• Fleury MJ, Touze A, Alvarez E, Carpentier G, Clavel C, Vautherot JF, Coursaget P. Identification of type-specific and cross-reactive neutralizing conformational epitopes on the major capsid protein of human papillomavirus type 31. Arch Virol 2006; 151:1511-23; PMID:16508703; http://dx.doi.org/10.1007/s00705-006-0734-y
   PubMedGoogle Scholar
• Roth SD, Sapp M, Streeck RE, Selinka HC. Characterization of neutralizing epitopes within the major capsid protein of human papillomavirus type 33. Virol J 2006; 3:83; PMID:17014700; http://dx.doi.org/10.1186/1743-422X-3-83
   PubMedGoogle Scholar
• Brown MJ, Seitz H, Towne V, Muller M, Finnefrock AC. Development of neutralizing monoclonal antibodies for oncogenic human papillomavirus types 31, 33, 45, 52, and 58. Clin Vaccine Immunol 2014; 21:587-93; PMID:24574536; http://dx.doi.org/10.1128/CVI.00773-13
   PubMed Web of Science ®Google Scholar
• Giroglou T, Sapp M, Lane C, Fligge C, Christensen ND, Streeck RE, Rose RC. Immunological analyses of human papillomavirus capsids. Vaccine 2001; 19:1783-93; PMID:11166904; http://dx.doi.org/10.1016/S0264-410X(00)00370-4
   PubMed Web of Science ®Google Scholar
• Joshi H, Cheluvaraja S, Somogyi E, Brown DR, Ortoleva P. A molecular dynamics study of loop fluctuation in human papillomavirus type 16 virus-like particles: a possible indicator of immunogenicity. Vaccine 2011; 29:9423-30; PMID:22027487; http://dx.doi.org/10.1016/j.vaccine.2011.10.039
   PubMedGoogle Scholar
• Orozco JJ, Carter JJ, Koutsky LA, Galloway DA. Humoral immune response recognizes a complex set of epitopes on human papillomavirus type 6 l1 capsomers. J VirolJ Virol 2005; 79:9503-14; PMID:16014913; http://dx.doi.org/10.1128/JVI.79.15.9503-9514.2005
   PubMedGoogle Scholar
• Li TC, Takeda N, Miyamura T, Matsuura Y, Wang JC, Engvall H, Hammar L, Xing L, Cheng RH. Essential elements of the capsid protein for self-assembly into empty virus-like particles of hepatitis E virus. J Virol 2005; 79:12999-3006; PMID:16189002; http://dx.doi.org/10.1128/JVI.79.20.12999-13006.2005
   PubMed Web of Science ®Google Scholar
• Li TC, Yamakawa Y, Suzuki K, Tatsumi M, Razak MA, Uchida T, Takeda N, Miyamura T. Expression and self-assembly of empty virus-like particles of hepatitis E virus. J Virol 1997; 71:7207-13; PMID:9311793
   PubMed Web of Science ®Google Scholar
• Li TC, Yoshimatsu K, Yasuda SP, Arikawa J, Koma T, Kataoka M, Ami Y, Suzaki Y, Mai le TQ, Hoa NT, et al. Characterization of self-assembled virus-like particles of rat hepatitis E virus generated by recombinant baculoviruses. J Gen Virol 2011; 92:2830-7; PMID:21865442; http://dx.doi.org/10.1099/vir.0.034835-0
   PubMedGoogle Scholar
• Guu TS, Liu Z, Ye Q, Mata DA, Li K, Yin C, Zhang J, Tao YJ. Structure of the hepatitis E virus-like particle suggests mechanisms for virus assembly and receptor binding. Proc Natl Acad Sci U S A 2009; 106:12992-7.
   PubMed Web of Science ®Google Scholar
• Xing L, Kato K, Li T, Takeda N, Miyamura T, Hammar L, Cheng RH. Recombinant hepatitis E capsid protein self-assembles into a dual-domain T = 1 particle presenting native virus epitopes. Virology 1999; 265:35-45; PMID:10603315; http://dx.doi.org/10.1006/viro.1999.0005
   PubMed Web of Science ®Google Scholar
• Xing L, Li TC, Mayazaki N, Simon MN, Wall JS, Moore M, Wang CY, Takeda N, Wakita T, Miyamura T, et al. Structure of hepatitis E virion-sized particle reveals an RNA-dependent viral assembly pathway. J Biol Chem 2010; 285:33175-83; PMID:20720013; http://dx.doi.org/10.1074/jbc.M110.106336
   PubMed Web of Science ®Google Scholar
• Huang CC, Nguyen D, Fernandez J, Yun KY, Fry KE, Bradley DW, Tam AW, Reyes GR. Molecular cloning and sequencing of the Mexico isolate of hepatitis E virus (HEV). Virology 1992; 191:550-8; PMID:1448913; http://dx.doi.org/10.1016/0042-6822(92)90230-M
   PubMed Web of Science ®Google Scholar
• Sreenivasan MA, Arankalle VA, Sehgal A, Pavri KM. Non-A, non-B epidemic hepatitis: visualization of virus-like particles in the stool by immune electron microscopy. J Gen Virol 1984; 65 ( Pt 5):1005-7; PMID:6427404; http://dx.doi.org/10.1099/0022-1317-65-5-1005
   PubMedGoogle Scholar
• Chen XS, Garcea RL, Goldberg I, Casini G, Harrison SC. Structure of small virus-like particles assembled from the L1 protein of human papillomavirus 16. Mol Cell 2000; 5:557-67; PMID:10882140; http://dx.doi.org/10.1016/S1097-2765(00)80449-9
   PubMed Web of Science ®Google Scholar
• Bishop B, Dasgupta J, Klein M, Garcea RL, Christensen ND, Zhao R, Chen XS. Crystal structures of four types of human papillomavirus L1 capsid proteins: understanding the specificity of neutralizing monoclonal antibodies. J Biol Chem 2007; 282:31803-11; PMID:17804402; http://dx.doi.org/10.1074/jbc.M706380200
   PubMed Web of Science ®Google Scholar
• Baker TS, Newcomb WW, Olson NH, Cowsert LM, Olson C, Brown JC. Structures of bovine and human papillomaviruses. Analysis by cryoelectron microscopy and three-dimensional image reconstruction. Biophys J 1991; 60:1445-56; PMID:1663794; http://dx.doi.org/10.1016/S0006-3495(91)82181-6
   PubMed Web of Science ®Google Scholar
• Trus BL, Roden RB, Greenstone HL, Vrhel M, Schiller JT, Booy FP. Novel structural features of bovine papillomavirus capsid revealed by a three-dimensional reconstruction to 9 A resolution. Nat Struct Biol 1997; 4:413-20; PMID:9145113; http://dx.doi.org/10.1038/nsb0597-413
   PubMedGoogle Scholar
• Modis Y, Trus BL, Harrison SC. Atomic model of the papillomavirus capsid. EMBO J 2002; 21:4754-62; PMID:12234916; http://dx.doi.org/10.1093/emboj/cdf494
   PubMed Web of Science ®Google Scholar
• Wolf M, Garcea RL, Grigorieff N, Harrison SC. Subunit interactions in bovine papillomavirus. Proc Natl Acad Sci U S A 2010; 107:6298-303.
   Google Scholar
• Grigorieff N, Harrison SC. Near-atomic resolution reconstructions of icosahedral viruses from electron cryo-microscopy. Curr Opin Struct Biol 2011; 21:265-73; PMID:21333526; http://dx.doi.org/10.1016/j.sbi.2011.01.008
   PubMed Web of Science ®Google Scholar
• Booy FP, Roden RB, Greenstone HL, Schiller JT, Trus BL. Two antibodies that neutralize papillomavirus by different mechanisms show distinct binding patterns at 13 A resolution. J Mol Biol 1998; 281:95-106; PMID:9680478; http://dx.doi.org/10.1006/jmbi.1998.1920
   PubMed Web of Science ®Google Scholar
• Combita AL, Touze A, Bousarghin L, Christensen ND, Coursaget P. Identification of two cross-neutralizing linear epitopes within the L1 major capsid protein of human papillomaviruses. J Virol 2002; 76:6480-6; PMID:12050360; http://dx.doi.org/10.1128/JVI.76.13.6480-6486.2002
   PubMed Web of Science ®Google Scholar
• Greiner VJ, Manin C, Larquet E, Ikhelef N, Greco F, Naville S, Milhiet PE, Ronzon F, Klymchenko A, Mely Y. Characterization of the structural modifications accompanying the loss of HBsAg particle immunogenicity. Vaccine 2014; 32:1049-54; PMID:24440114; http://dx.doi.org/10.1016/j.vaccine.2014.01.012
   PubMedGoogle Scholar
• Mulder AM, Carragher B, Towne V, Meng Y, Wang Y, Dieter L, Potter CS, Washabaugh MW, Sitrin RD, Zhao Q. Toolbox for non-intrusive structural and functional analysis of recombinant VLP based vaccines: a case study with hepatitis B vaccine. PloS one 2012; 7:e33235; PMID:22493667; http://dx.doi.org/10.1371/journal.pone.0033235
   PubMedGoogle Scholar
• Greiner VJ, Egele C, Oncul S, Ronzon F, Manin C, Klymchenko A, Mely Y. Characterization of the lipid and protein organization in HBsAg viral particles by steady-state and time-resolved fluorescence spectroscopy. Biochimie 2010; 92:994-1002; PMID:20420879; http://dx.doi.org/10.1016/j.biochi.2010.04.014
   PubMed Web of Science ®Google Scholar
• Mangold CM, Streeck RE. Mutational analysis of the cysteine residues in the hepatitis B virus small envelope protein. J Virol 1993; 67:4588-97; PMID:8392600
   PubMed Web of Science ®Google Scholar
• Gilbert RJ, Beales L, Blond D, Simon MN, Lin BY, Chisari FV, Stuart DI, Rowlands DJ. Hepatitis B small surface antigen particles are octahedral. Proc Natl Acad Sci U S A 2005; 102:14783-8.
   Google Scholar
• Iwarson S, Tabor E, Thomas HC, Goodall A, Waters J, Snoy P, Shih JW, Gerety RJ. Neutralization of hepatitis B virus infectivity by a murine monoclonal antibody: an experimental study in the chimpanzee. J Med Virol 1985; 16:89-96; PMID:2413167; http://dx.doi.org/10.1002/jmv.1890160112
   PubMed Web of Science ®Google Scholar
• Shearer MH, Sureau C, Dunbar B, Kennedy RC. Structural characterization of viral neutralizing monoclonal antibodies to hepatitis B surface antigen. Mol Immunol 1998; 35:1149-60; PMID:10199389; http://dx.doi.org/10.1016/S0161-5890(98)00110-2
   PubMedGoogle Scholar
• Zhu Y, Zhang T, Zhao J, Weng Z, Yuan Q, Li S, Zhang J, Xia N, Zhao Q. Toward the development of monoclonal antibody-based assays to probe virion-like epitopes in hepatitis B vaccine antigen. Hum Vacci Immunother 2014; 10:1013-23; PMID:24499806; http://dx.doi.org/10.4161/hv.27753
   PubMed Web of Science ®Google Scholar
• Waters J, Pignatelli M, Galpin S, Ishihara K, Thomas HC. Virus-neutralizing antibodies to hepatitis B virus: the nature of an immunogenic epitope on the S gene peptide. J Gen Virol 1986; 67 ( Pt 11):2467-73; PMID:2431101; http://dx.doi.org/10.1099/0022-1317-67-11-2467
   PubMedGoogle Scholar
• Waters JA, Brown SE, Steward MW, Howard CR, Thomas HC. Analysis of the antigenic epitopes of hepatitis B surface antigen involved in the induction of a protective antibody response. Virus Res 1992; 22:1-12; PMID:1371369; http://dx.doi.org/10.1016/0168-1702(92)90085-N
   PubMed Web of Science ®Google Scholar
• Zhao Q, Towne V, Brown M, Wang Y, Abraham D, Oswald CB, Gimenez JA, Washabaugh MW, Kennedy R, Sitrin RD. In-depth process understanding of RECOMBIVAX HB(R) maturation and potential epitope improvements with redox treatment: multifaceted biochemical and immunochemical characterization. Vaccine 2011; 29:7936-41; PMID:21871939; http://dx.doi.org/10.1016/j.vaccine.2011.08.070
   PubMed Web of Science ®Google Scholar
• Zhao Q, Wang Y, Abraham D, Towne V, Kennedy R, Sitrin RD. Real time monitoring of antigenicity development of HBsAg virus-like particles (VLPs) during heat- and redox-treatment. Biochem Biophys Res Commun 2011; 408:447-53; PMID:21527246; http://dx.doi.org/10.1016/j.bbrc.2011.04.048
   PubMed Web of Science ®Google Scholar
• Li M, Beard P, Estes PA, Lyon MK, Garcea RL. Intercapsomeric disulfide bonds in papillomavirus assembly and disassembly. J Virol 1998; 72:2160-7; PMID:9499072
   PubMed Web of Science ®Google Scholar
• Ishii Y, Kondo K, Matsumoto T, Tanaka K, Shinkai-Ouchi F, Hagiwara K, Kanda T. Thiol-reactive reagents inhibits intracellular trafficking of human papillomavirus type 16 pseudovirions by binding to cysteine residues of major capsid protein L1. Virol J 2007; 4:110; PMID:17961263; http://dx.doi.org/10.1186/1743-422X-4-110
   PubMedGoogle Scholar
• Ishii Y, Tanaka K, Kanda T. Mutational analysis of human papillomavirus type 16 major capsid protein L1: the cysteines affecting the intermolecular bonding and structure of L1-capsids. Virology 2003; 308:128-36; PMID:12706096; http://dx.doi.org/10.1016/S0042-6822(02)00099-5
   PubMedGoogle Scholar
• Zhao Q, Allen MJ, Wang Y, Wang B, Wang N, Shi L, Sitrin RD. Disassembly and reassembly improves morphology and thermal stability of human papillomavirus type 16 virus-like particles. Nanomedicine2012; 8:1182-9; PMID:22306156; http://dx.doi.org/10.1016/j.nano.2012.01.007
   PubMed Web of Science ®Google Scholar
• Zhao Q, Modis Y, High K, Towne V, Meng Y, Wang Y, Alexandroff J, Brown M, Carragher B, Potter CS, et al. Disassembly and reassembly of human papillomavirus virus-like particles produces more virion-like antibody reactivity. VirolJ 2012; 9:52; PMID:22356831; http://dx.doi.org/10.1186/1743-422X-9-52
   PubMedGoogle Scholar
• Yang C, Pan H, Wei M, Zhang X, Wang N, Gu Y, Du H, Zhang J, Li S, Xia N. Hepatitis E virus capsid protein assembles in 4M urea in the presence of salts. Protein Science 2013; 22:314-26; PMID:23281113; http://dx.doi.org/10.1002/pro.2213
   PubMed Web of Science ®Google Scholar
• McPherson CE. Development of a novel recombinant influenza vaccine in insect cells. Biologicals 2008; 36:350-3; PMID:18804387; http://dx.doi.org/10.1016/j.biologicals.2008.08.001
   PubMed Web of Science ®Google Scholar
• Cox MM. Recombinant protein vaccines produced in insect cells. Vaccine 2012; 30:1759-66; PMID:22265860; http://dx.doi.org/10.1016/j.vaccine.2012.01.016
   PubMed Web of Science ®Google Scholar
• Wang K, Holtz KM, Anderson K, Chubet R, Mahmoud W, Cox MM. Expression and purification of an influenza hemagglutinin-one step closer to a recombinant protein-based influenza vaccine. Vaccine 2006; 24:2176-85; PMID:16310896; http://dx.doi.org/10.1016/j.vaccine.2005.11.005
   PubMed Web of Science ®Google Scholar
• Cox MM, Hashimoto Y. A fast track influenza virus vaccine produced in insect cells. J Invertebr Pathol 2011; 107 Suppl:S31-41; PMID:21784229; http://dx.doi.org/10.1016/j.jip.2011.05.003
   PubMed Web of Science ®Google Scholar
• Cox MM, Karl Anderson D. Production of a novel influenza vaccine using insect cells: protection against drifted strains. Influenza Other Respir Viruses 2007; 1:35-40; PMID:19453478; http://dx.doi.org/10.1111/j.1750-2659.2006.00007.x
   PubMed Web of Science ®Google Scholar
• Feshchenko E, Rhodes DG, Felberbaum R, McPherson C, Rininger JA, Post P, Cox MM. Pandemic influenza vaccine: characterization of A/California/07/2009 (H1N1) recombinant hemagglutinin protein and insights into H1N1 antigen stability. BMC Biotechnol 2012; 12:77; PMID:23110350; http://dx.doi.org/10.1186/1472-6750-12-77
   PubMed Web of Science ®Google Scholar
• Keitel WA, Treanor JJ, El Sahly HM, Gilbert A, Meyer AL, Patriarca PA, Cox MM. Comparative immunogenicity of recombinant influenza hemagglutinin (rHA) and trivalent inactivated vaccine (TIV) among persons > or =65 years old. Vaccine 2009; 28:379-85; PMID:19879222; http://dx.doi.org/10.1016/j.vaccine.2009.10.037
   PubMed Web of Science ®Google Scholar
• King JC, Jr., Cox MM, Reisinger K, Hedrick J, Graham I, Patriarca P. Evaluation of the safety, reactogenicity and immunogenicity of FluBlok trivalent recombinant baculovirus-expressed hemagglutinin influenza vaccine administered intramuscularly to healthy children aged 6-59 months. Vaccine 2009; 27:6589-94; PMID:19716456; http://dx.doi.org/10.1016/j.vaccine.2009.08.032
   PubMed Web of Science ®Google Scholar
• Baxter R, Patriarca PA, Ensor K, Izikson R, Goldenthal KL, Cox MM. Evaluation of the safety, reactogenicity and immunogenicity of FluBlok(R) trivalent recombinant baculovirus-expressed hemagglutinin influenza vaccine administered intramuscularly to healthy adults 50-64 years of age. Vaccine 2011; 29:2272-8; PMID:21277410; http://dx.doi.org/10.1016/j.vaccine.2011.01.039
   PubMed Web of Science ®Google Scholar
• Cox MM, Hollister JR. FluBlok, a next generation influenza vaccine manufactured in insect cells. Biologicals 2009; 37:182-9; PMID:19297194; http://dx.doi.org/10.1016/j.biologicals.2009.02.014
   PubMed Web of Science ®Google Scholar
• Cox MM, Patriarca PA, Treanor J. FluBlok, a recombinant hemagglutinin influenza vaccine. Influenza Other Respirat Viruses 2008; 2:211-9; PMID:19453397; http://dx.doi.org/10.1111/j.1750-2659.2008.00053.x
   PubMed Web of Science ®Google Scholar
• Treanor JJ, El Sahly H, King J, Graham I, Izikson R, Kohberger R, Patriarca P, Cox M. Protective efficacy of a trivalent recombinant hemagglutinin protein vaccine (FluBlok(R)) against influenza in healthy adults: a randomized, placebo-controlled trial. Vaccine 2011; 29:7733-9; PMID:21835220; http://dx.doi.org/10.1016/j.vaccine.2011.07.128
   PubMed Web of Science ®Google Scholar
• Treanor JJ, Schiff GM, Hayden FG, Brady RC, Hay CM, Meyer AL, Holden-Wiltse J, Liang H, Gilbert A, Cox M. Safety and immunogenicity of a baculovirus-expressed hemagglutinin influenza vaccine: a randomized controlled trial. JAMA 2007; 297:1577-82; PMID:17426277; http://dx.doi.org/10.1001/jama.297.14.1577
   PubMed Web of Science ®Google Scholar
• Kang SM, Song JM, Quan FS, Compans RW. Influenza vaccines based on virus-like particles. Virus Res 2009; 143:140-6; PMID:19374929; http://dx.doi.org/10.1016/j.virusres.2009.04.005
   PubMed Web of Science ®Google Scholar
• Song H, Wittman V, Byers A, Tapia T, Zhou B, Warren W, Heaton P, Connolly K. In vitro stimulation of human influenza-specific CD8+ T cells by dendritic cells pulsed with an influenza virus-like particle (VLP) vaccine. Vaccine 2010; 28:5524-32; PMID:20600506; http://dx.doi.org/10.1016/j.vaccine.2010.06.044
   PubMedGoogle Scholar
• Khurana S, Wu J, Verma N, Verma S, Raghunandan R, Manischewitz J, King LR, Kpamegan E, Pincus S, Smith G, et al. H5N1 virus-like particle vaccine elicits cross-reactive neutralizing antibodies that preferentially bind to the oligomeric form of influenza virus hemagglutinin in humans. J Virol 2011; 85:10945-54; PMID:21865396; http://dx.doi.org/10.1128/JVI.05406-11
   PubMed Web of Science ®Google Scholar
• Bright RA, Carter DM, Crevar CJ, Toapanta FR, Steckbeck JD, Cole KS, Kumar NM, Pushko P, Smith G, Tumpey TM, et al. Cross-clade protective immune responses to influenza viruses with H5N1 HA and NA elicited by an influenza virus-like particle. PloS one 2008; 3:e1501; PMID:18231588; http://dx.doi.org/10.1371/journal.pone.0001501
   PubMed Web of Science ®Google Scholar
• Pushko P, Tumpey TM, Van Hoeven N, Belser JA, Robinson R, Nathan M, Smith G, Wright DC, Bright RA. Evaluation of influenza virus-like particles and Novasome adjuvant as candidate vaccine for avian influenza. Vaccine 2007; 25:4283-90; PMID:17403562; http://dx.doi.org/10.1016/j.vaccine.2007.02.059
   PubMed Web of Science ®Google Scholar
• Akahata W, Yang ZY, Andersen H, Sun S, Holdaway HA, Kong WP, Lewis MG, Higgs S, Rossmann MG, Rao S, et al. A virus-like particle vaccine for epidemic Chikungunya virus protects nonhuman primates against infection. Nat Med 2010; 16:334-8; PMID:20111039; http://dx.doi.org/10.1038/nm.2105
   PubMed Web of Science ®Google Scholar
• Metz SW, Gardner J, Geertsema C, Le TT, Goh L, Vlak JM, Suhrbier A, Pijlman GP. Effective chikungunya virus-like particle vaccine produced in insect cells. PLoS Negl Trop Dis 2013; 7:e2124; PMID:23516657; http://dx.doi.org/10.1371/journal.pntd.0002124
   PubMed Web of Science ®Google Scholar
• Metz SW, Martina BE, van den Doel P, Geertsema C, Osterhaus AD, Vlak JM, Pijlman GP. Chikungunya virus-like particles are more immunogenic in a lethal AG129 mouse model compared to glycoprotein E1 or E2 subunits. Vaccine 2013; 31:6092-6; PMID:24099875; http://dx.doi.org/10.1016/j.vaccine.2013.09.045
   PubMed Web of Science ®Google Scholar
• Pialoux G, Gauzere BA, Jaureguiberry S, Strobel M. Chikungunya, an epidemic arbovirosis. Lancet Infect Dis 2007; 7:319-27; PMID:17448935; http://dx.doi.org/10.1016/S1473-3099(07)70107-X
   PubMed Web of Science ®Google Scholar
• Burt FJ, Rolph MS, Rulli NE, Mahalingam S, Heise MT. Chikungunya: a re-emerging virus. Lancet 2012; 379:662-71; PMID:22100854; http://dx.doi.org/10.1016/S0140-6736(11)60281-X
   PubMed Web of Science ®Google Scholar
• Thiberville SD, Moyen N, Dupuis-Maguiraga L, Nougairede A, Gould EA, Roques P, de Lamballerie X. Chikungunya fever: epidemiology, clinical syndrome, pathogenesis and therapy. Antiviral Res 2013; 99:345-70; PMID:23811281; http://dx.doi.org/10.1016/j.antiviral.2013.06.009
   PubMed Web of Science ®Google Scholar
• Chang LJ, Dowd KA, Mendoza FH, Saunders JG, Sitar S, Plummer SH, Yamshchikov G, Sarwar UN, Hu Z, Enama ME, et al. Safety and tolerability of chikungunya virus-like particle vaccine in healthy adults: a phase 1 dose-escalation trial. Lancet 2014; 384:2046-52; PMID:25132507; http://dx.doi.org/10.1016/S0140-6736(14)61185-5
   PubMed Web of Science ®Google Scholar
• Kam YW, Lum FM, Teo TH, Lee WW, Simarmata D, Harjanto S, Chua CL, Chan YF, Wee JK, Chow A, et al. Early neutralizing IgG response to Chikungunya virus in infected patients targets a dominant linear epitope on the E2 glycoprotein. EMBO Mol Med 2012; 4:330-43; PMID:22389221; http://dx.doi.org/10.1002/emmm.201200213
   PubMed Web of Science ®Google Scholar
• Kam YW, Simarmata D, Chow A, Her Z, Teng TS, Ong EK, Renia L, Leo YS, Ng LF. Early appearance of neutralizing immunoglobulin G3 antibodies is associated with chikungunya virus clearance and long-term clinical protection. J Infect Diss 2012; 205:1147-54; PMID:22389226; http://dx.doi.org/10.1093/infdis/jis033
   PubMed Web of Science ®Google Scholar
• Lee CY, Kam YW, Fric J, Malleret B, Koh EG, Prakash C, Huang W, Lee WW, Lin C, Lin RT, et al. Chikungunya virus neutralization antigens and direct cell-to-cell transmission are revealed by human antibody-escape mutants. PLoS Pathog 2011; 7:e1002390; PMID:22144891; http://dx.doi.org/10.1371/journal.ppat.1002390
   PubMed Web of Science ®Google Scholar
• Warter L, Lee CY, Thiagarajan R, Grandadam M, Lebecque S, Lin RT, Bertin-Maghit S, Ng LF, Abastado JP, Despres P, et al. Chikungunya virus envelope-specific human monoclonal antibodies with broad neutralization potency. J Immunol 2011; 186:3258-64; PMID:21278338; http://dx.doi.org/10.4049/jimmunol.1003139
   PubMed Web of Science ®Google Scholar
• Lee H, Brendle SA, Bywaters SM, Guan J, Ashley RE, Yoder JD, Makhov AM, Conway JF, Christensen ND, Hafenstein S. A cryo-electron microscopy study identifies the complete H16.V5 epitope and reveals global conformational changes initiated by binding of the neutralizing antibody fragment. Journal of virology 2015; 89:1428-38
   PubMed Web of Science ®Google Scholar
• Schofield T. In vitro versus in vivo concordance: a case study of the replacement of an animal potency test with an immunochemical assay. Dev Biol 2002; 111:299-304; PMID:12678253
   PubMedGoogle Scholar
• Waters JA, Pignatelli M, Brown D, O'Rourke S, Lever A, Thomas HC. The immune response to hepatitis B virus. Postgrad Med J 1987; 63 Suppl 2:51-6; PMID:2446303
   PubMedGoogle Scholar
• Varsani A, Williamson AL, de Villiers D, Becker I, Christensen ND, Rybicki EP. Chimeric human papillomavirus type 16 (HPV-16) L1 particles presenting the common neutralizing epitope for the L2 minor capsid protein of HPV-6 and HPV-16. J Virol 2003; 77:8386-93; PMID:12857908; http://dx.doi.org/10.1128/JVI.77.15.8386-8393.2003
   PubMed Web of Science ®Google Scholar
• Shank-Retzlaff M, Wang F, Morley T, Anderson C, Hamm M, Brown M, Rowland K, Pancari G, Zorman J, Lowe R, et al. Correlation between mouse potency and in vitro relative potency for human papillomavirus Type 16 virus-like particles and Gardasil vaccine samples. Hum Vaccin 2005; 1:191-7; PMID:17012876; http://dx.doi.org/10.4161/hv.1.5.2126
   PubMed Web of Science ®Google Scholar
• Deschuyteneer M, Elouahabi A, Plainchamp D, Plisnier M, Soete D, Corazza Y, Lockman L, Giannini S, Deschamps M. Molecular and structural characterization of the L1 virus-like particles that are used as vaccine antigens in Cervarix, the AS04-adjuvanted HPV-16 and -18 cervical cancer vaccine. Hum Vaccin 2010; 6:407-19; PMID:20953154; http://dx.doi.org/10.4161/hv.6.5.11023
   PubMed Web of Science ®Google Scholar
• Shank-Retzlaff ML, Zhao Q, Anderson C, Hamm M, High K, Nguyen M, Wang F, Wang N, Wang B, Wang Y, et al. Evaluation of the thermal stability of Gardasil. Hum Vaccin 2006; 2:147-54; PMID:17012891; http://dx.doi.org/10.4161/hv.2.4.2989
   PubMed Web of Science ®Google Scholar